Insights & Publications
© 2018 Debevoise & Plimpton LLP
The Latest on the Trump Administration’s Drug Pricing Initiatives
21 February 2018
View Client Update
President Trump stated during the State of the Union that addressing high drug prices is a top administration priority. Since that time, there have been a number of developments relating to drug pricing issues.
The Balanced Budget Act, which was signed by President Trump on February 9, contains a provision that will shrink the coverage gap in Medicare Plan D prescription drug coverage and will shift much of the cost of prescription drugs sold to patients in the coverage gap to the pharmaceutical industry.
The President’s budget, which was released on February 12, includes a number of proposals that are designed to reduce prescription drug costs, particularly for Medicare Part D beneficiaries. However, the effect of these proposals appears limited, and it is unclear whether Congress will enact them.
Andrew L. Bab
Jennifer L. Chu
Mark P. Goodman
Maura Kathleen Monaghan
View More Authors
Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
DOJ Memorandum Addressing Agency Guidance
Perpetually Liable? What the California Supreme Court Decision Means for Innovator Pharmaceutical Companies
Toxics Law Reporter
Debevoise Advises Johnson & Johnson on a Global Co-Development and Commercialization Agreement for TD-1473
UK Modern Slavery Act Transparency Statement
Debevoise Women's Review